Drug disappoints in recurrent glioblastoma

5 February 2010 | by Nicola Garrett Print this article Comments Share this article
Hopes for treating recurrent glioblastoma with the targeted anti-angiogenic enzastaurin have been dashed by disappointing phase III results....

Want to read complete article? Please Sign in or Register.

Journals

Members of Oncology Update can access the following journals for free:

Most viewed articles this week

Recent comments

Related sites